中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 8
Aug.  2013

Comparative study of radiofrequency ablation and percutaneous ethanol injection in treating postoperative recurrence of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2013.08.009
  • Published Date: 2013-08-20
  • Objective To compare the clinical effects of radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) in treating postoperative recurrence of hepatocellular carcinoma (HCC) and to provide reference for clinical treatment of recurrent HCC. Methods A retrospective analysis was performed on the clinical data of 175 patients who had a single recurrent lesion after surgical treatment of HCC from August 2007 to January 2010. These patients were divided into PEI group (n=101) and RFA group (n=74) according to the modalities of treatment for recurrent HCC. All cases underwent color Doppler ultrasound and contrast-enhanced ultrasound or CT before and after treatment. The two groups were compared in terms of number of treatments, complete ablation rate, and complication rate. The 1-, 2-, and 3-year survival rates after treatment were also recorded. The measurement data were subjected to t-test, while the enumeration data were subjected to chi-square test. Results The PEI group had a significantly larger mean number of treatments than the RFA group (P<0.05). There was no significant difference in complication rate between the two groups (P>0.05). For the recurrent lesions smaller than 2.0 cm in diameter, the complete ablation rate showed no significant difference between the RFA group and PEI group (P>0.05), while this rate was significantly higher in the RFA group than in the PEI group for the recurrent lesions with a diameter of 2.0-5.0 cm (P<005). Among the patients with recurrent lesions smaller than 2.0 cm in diameter, those receiving PEI had 1-, 2-, and 3-year survival rates of 89.1%, 69.1%, and 49.1%, respectively, versus 90.2%, 70.7%, and 53.7% for those receiving RFA (P>0.05); among the patients with recurrent lesions with a diameter of 2.0-5.0 cm, those receiving PEI had significantly lower 1-, 2-, and 3-year survival rates than those receiving RFA (63.0% vs 84.8%, P<0.05; 43.5% vs 66.7%, P<0.05; 21.7% vs 45.5%, P<0.05). Conclusion RFA and PEI lead to similar survival rates in patients with recurrent lesions smaller than 2.0 cm in diameter after surgical treatment of HCC, but RFA produces a better survival than PEI in those with recurrent lesions with a diameter of 2.0-5.0 cm.

     

  • Relative Articles

    [1]Min WANG, Wenping LUO, Guanhua ZHANG, Xinyan ZHAO, Hong MA, Ying TIAN, Yu WANG. Diagnostic value of FibroTouch, FibroScan, and acoustic radiation force impulse for liver fibrosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(4): 817-822. doi: 10.3969/j.issn.1001-5256.2021.04.019
    [2]Li ZhengXin, Chen YangYi, Zhao ZhiMin, Lyu Jing, Chen GaoFeng, Liu ChengHai. Influencing factors for FibroTouch measurements in chronic hepatitis B patients based on liver pathology[J]. Journal of Clinical Hepatology, 2019, 35(2): 338-344. doi: 10.3969/j.issn.1001-5256.2019.02.019
    [3]Leng XueJun, Yan XueBing. Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J]. Journal of Clinical Hepatology, 2018, 34(9): 1891-1895. doi: 10.3969/j.issn.1001-5256.2018.09.013
    [4]Li JingBo, Liu Shu, Wen Bo, Gao Nan, Wang BingYuan. Clinical significance of Fibro Touch,ultrasound,and computed tomography in diagnosis of fatty liver disease: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(3): 459-462. doi: 10.3969/j.issn.1001-5256.2016.03.011
    [5]Cao HaiYang, Wu XiaoFeng, Lin DongDong. Research advances in fatty donor liver in liver transplantation[J]. Journal of Clinical Hepatology, 2015, 31(7): 1140-1143. doi: 10.3969/j.issn.1001-5256.2015.07.036
    [6]Zhang Yu, Cheng Jun. Hepatitis C virus related fatty liver[J]. Journal of Clinical Hepatology, 2015, 31(7): 1034-1037. doi: 10.3969/j.issn.1001-5256.2015.07.009
    [7]Wu Na, Zhang MingYuan, Wu RuiHong, Zhang YingWen, Jin JingLan, Zhu YingQiao, Niu JunQi. Diagnostic values of FibroScan and FibroTouch for liver fibrosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2014, 30(7): 624-627. doi: 10.3969/j.issn.1001-5256.2014.07.012
    [8]Tang ShaoShan, Zhao GuoJia, Wang YiJiao. Assessment of ultrasound elastography to grade hepatic steatosis in a rat model[J]. Journal of Clinical Hepatology, 2013, 29(4): 282-285.
    [9]Shi JunPing, Xun YunHao. Progress in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 890-893. doi: 10.3969/j.issn.1001-5256.2013.12.004
    [10]Zhou ShuYun, Sun ZheYing. Therapeutic efficacy of polyunsaturated phosphatidylcholine on fatty liver disease[J]. Journal of Clinical Hepatology, 2010, 26(3): 286-287.
    [11]Xiang GuoQing, Meng XiaoDan, Wang BingYuan. Prevalence of fatty liver among people with different occupation in Shenyang[J]. Journal of Clinical Hepatology, 2010, 26(3): 283-285.
    [12]Qin YongJun, Sun JieSheng, Wang BingYuan, Liu PengLiang, Sun FuRong, Liu CuiXiang, Xie DaWei. The differences of the blood routine indexes in patients with fatty liver and non-fatty liver[J]. Journal of Clinical Hepatology, 2010, 26(2): 163-166.
    [13]Xu YuWu, Liu YingZi, Fan JianGao, Yang Lin.

    Preliminary study on quantification of ultrasonographic classification of fatty liver

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 267-268+280.
    [14]Wan Hong, Li Ling, Tang YanPing. study on fatty liver prevalence in the government officers in Lanzhou area[J]. Journal of Clinical Hepatology, 2008, 24(4): 261-262.
    [16]Hu DeYou. Ultrasonic monitoring of relationship between exercise and fatty liver[J]. Journal of Clinical Hepatology, 2004, 20(1): 34-35.
    [17]Ding YanHua, He ShuMei, Wang XiaoWei, Xu MaoFeng, Niu JunQi. The clinical feature of 198 patients with fatty liver[J]. Journal of Clinical Hepatology, 2004, 20(5): 287-288.
  • Cited by

    Periodical cited type(25)

    1. 胡馨月,文良志,王斌,魏艳玲,崔红利,陈东风. 2410例肝窦阻塞综合征患者临床特征的系统分析. 胃肠病学和肝病学杂志. 2024(01): 9-14 .
    2. 张万钦,朱芳. 狗舌草致肝窦阻塞综合征. 药物不良反应杂志. 2024(01): 56-58 .
    3. 刘盼盼,陶运生. 乙肝肝硬化合并肝窦阻塞综合征1例. 现代医药卫生. 2024(16): 2877-2880 .
    4. 白婷婷,刘钰懿,陈东风. 肝脏血管性疾病诊断与鉴别诊断. 实用肝脏病杂志. 2023(02): 153-155 .
    5. 李立,罗轶,李丽莉,蒋湘,黄燕红. 白背三七中吡咯里西啶生物碱的含量分析及风险评价. 西北药学杂志. 2023(05): 31-36 .
    6. 贾翠宇,赵大伟,冯骥良,宋文艳,王欣欣. 肝窦阻塞综合征的临床和影像学表现. 临床放射学杂志. 2022(02): 284-288 .
    7. 石玉芝,陈芳,许剑. 土三七致大鼠肝窦阻塞综合征发病机制研究. 现代医学与健康研究电子杂志. 2022(06): 99-103 .
    8. 李宗明,韩新巍,丁鹏绪,周朋利,焦德超,雷钦宇,徐苗. 经颈静脉肝内门体分流术治疗慢性期肝小静脉闭塞症疗效观察. 郑州大学学报(医学版). 2022(03): 422-426 .
    9. 尚亚男,徐浩,郭潇,王仲恺. 土三七致肝窦阻塞综合征的临床及CT特征研究. 医学影像学杂志. 2022(08): 1317-1322 .
    10. 昝珂,周颖,李耀磊,王莹,金红宇,左甜甜,马双成. 赤小豆中吡咯里西啶生物碱氮氧化物含量测定及安全风险评估. 中国药物警戒. 2022(11): 1186-1190 .
    11. 昝珂,蒋黄卉,金红宇,马双成,赵磊,孙艳涛. 中药肝毒性吡咯里西啶生物碱的质量控制研究进展. 药物分析杂志. 2021(04): 572-578 .
    12. 昝珂,周颖,李耀磊,左甜甜,金红宇,王莹,马双成. 罗布麻叶中肝毒性成分吡咯里西啶生物碱的含量分析及其初步风险评估. 中国药事. 2021(07): 757-762 .
    13. 昝珂,周颖,李耀磊,王莹,刘丽娜,金红宇,左甜甜,马双成. UPLC-MS/MS测定一点红不同部位中6种吡咯里西啶生物碱的含量. 中国中药杂志. 2021(17): 4456-4461 .
    14. 昝珂,陈翠玲,周颖,左甜甜,金红宇,王莹,马双成. 马鞭草中6个肝毒性吡咯里西啶生物碱的含量测定及风险评估. 中国实验方剂学杂志. 2021(24): 157-162 .
    15. 李惠贞,蔡剑鸣,董景辉,刘渊,任洪伟,安维民. 肝窦阻塞综合征患者临床及影像学表现分析. 中华消化病与影像杂志(电子版). 2021(06): 263-267 .
    16. 昝珂,李耀磊,周颖,左甜甜,金红宇,王莹,马双成. UPLC-MS/MS法测定大蓟中7个吡咯里西啶生物碱的含量及初步风险评估. 药物分析杂志. 2021(10): 1690-1696 .
    17. 昝珂,周颖,李耀磊,王莹,金红宇,左甜甜,刘丽娜,马双成. 半枝莲中肝毒性成分吡咯里西啶生物碱含量分析及初步风险评估. 药物评价研究. 2021(12): 2608-2613 .
    18. 昝珂,陈翠玲,周颖,金红宇,马双成,王莹. 超高效液相色谱串联质谱法测定木贼中4种吡咯里西啶生物碱. 化学分析计量. 2021(12): 38-42 .
    19. 昝珂,周颖,李耀磊,左甜甜,金红宇,王莹,马双成. 灯盏细辛中吡咯里西啶生物碱的含量分析及其肝毒性风险评估. 中国现代中药. 2021(11): 1897-1901 .
    20. 戚汝平,董景辉,李勇武,安维民,任洪伟,刘渊. 26例肝窦阻塞综合征临床及影像分析. 肝脏. 2020(02): 162-165 .
    21. 徐楠,李江,谢琴秀. 43例吡咯生物碱相关肝窦阻塞综合征临床特征及预后分析. 安徽医学. 2020(07): 797-800 .
    22. 刘少松,周晓东. 吡咯烷生物碱诱导肝窦阻塞综合征的研究进展. 临床内科杂志. 2020(04): 256-259 .
    23. 刘贞利,范作鹏,勾钰淞,柳雅立,张晶. 不同类型肝窦阻塞综合征的临床特征、发病机制与诊治. 临床肝胆病杂志. 2019(01): 208-212 . 本站查看
    24. 尹昕茹,陈东风. 隐源性肝硬化诊治的临床思维. 医学研究生学报. 2019(06): 576-579 .
    25. 亓传旺,咸建春,肖丽,李阳. 土三七致肝窦阻塞综合征5例临床分析. 中国中西医结合消化杂志. 2019(07): 548-551 .

    Other cited types(6)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 5.5 %FULLTEXT: 5.5 %META: 91.6 %META: 91.6 %PDF: 2.9 %PDF: 2.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 2.6 %其他: 2.6 %其他: 0.3 %其他: 0.3 %上海: 2.3 %上海: 2.3 %北京: 10.4 %北京: 10.4 %南宁: 0.3 %南宁: 0.3 %吉林: 1.2 %吉林: 1.2 %哥伦布: 0.3 %哥伦布: 0.3 %张家口: 4.6 %张家口: 4.6 %扬州: 0.3 %扬州: 0.3 %昆明: 0.9 %昆明: 0.9 %杭州: 0.3 %杭州: 0.3 %芒廷维尤: 39.6 %芒廷维尤: 39.6 %苏州: 0.3 %苏州: 0.3 %莫斯科: 1.4 %莫斯科: 1.4 %西宁: 34.4 %西宁: 34.4 %长春: 0.6 %长春: 0.6 %长沙: 0.3 %长沙: 0.3 %其他其他上海北京南宁吉林哥伦布张家口扬州昆明杭州芒廷维尤苏州莫斯科西宁长春长沙

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (3996) PDF downloads(606) Cited by(31)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return